Cero Therapeutics Holdings, INC S-1 registration statements
Registration statements, filed ahead of a public offering, with the business description and financials a first-time investor sees.
OQB
CERO Therapeutics Holdings, Inc. filed an S-1 registration statement for the resale of up to 729.6 million common shares by Keystone Capital Partners, LLC, following its delisting from Nasdaq to OTCQB.
OQB
CERo Therapeutics Holdings, Inc. filed an S-1 registration statement for the potential resale of up to 12.5 million common shares by Keystone Capital Partners, LLC, aiming to secure up to $25 million in gross proceeds to fund its innovative CER-T cell cancer therapies despite ongoing significant losses and going concern doubts.
OQB
CERo Therapeutics aims to raise capital to advance its clinical programs and for general corporate purposes through a public offering of common stock, pre-funded warrants, and common warrants.
OQB
CERo Therapeutics is offering up to 4 million shares of common stock, pre-funded warrants, and common warrants in a new offering.
OQB
CERo Therapeutics Holdings, Inc. is launching a public offering of common stock and warrants to raise capital while facing potential delisting from the Nasdaq.
OQB
S-1: CERo Therapeutics Files for Resale of Up to 210 Million Common Shares by Keystone Capital Partners
CERo Therapeutics Holdings, Inc. has filed a prospectus for the potential resale of up to 210 million shares of its common stock by Keystone Capital Partners, LLC.
OQB
S-1/A: CERo Therapeutics Files for Resale of Up to 638.5 Million Shares Amidst Nasdaq Compliance Issues
CERo Therapeutics Holdings, Inc. is registering for resale up to 638.5 million shares of its common stock by existing securityholders, while also facing potential delisting from Nasdaq due to non-compliance with listing requirements.
OQB
CERo Therapeutics Holdings, Inc. files an amendment to its Form S-1 registration statement related to the offering and sale of common stock by selling securityholders.
OQB
CERo Therapeutics is registering for resale a significant number of common shares, potentially impacting its stock price.
OQB
CERo Therapeutics is registering for resale up to 44.1 million shares of common stock following its business combination, including shares held by selling securityholders and those issuable upon warrant exercises.
OQB
CERo Therapeutics is registering for resale a significant number of common shares and warrants, potentially impacting its stock price and future capital raising efforts.
OQB
CERo Therapeutics is registering for resale up to 44.5 million shares of common stock, including shares held by selling securityholders and those issuable upon warrant exercises, following its recent business combination.
OQB
CERo Therapeutics is registering for the potential resale of up to 26.6 million shares of common stock by existing security holders, aiming to bolster working capital.
OQB
CERo Therapeutics is registering for the potential resale of up to 26.6 million shares of its common stock by Keystone Capital Partners and Arena Business Solutions Global SPC II, aiming to raise up to $48.8 million.